{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:25:55Z","timestamp":1780525555094,"version":"3.54.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["213096"],"award-info":[{"award-number":["213096"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute for Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1 UM1 AI164561-01"],"award-info":[{"award-number":["1 UM1 AI164561-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3 Lluita Contra les Infeccions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To compare the effects of first-line antiretroviral therapy (ART) with dolutegravir plus lamivudine (DTG + 3TC) versus dolutegravir plus emtricitabine\/tenofovir alafenamide (DTG + FTC\/TAF) on the human immunodeficiency virus type 1 (HIV-1) reservoir and immune activation biomarkers in people with HIV (PWH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>DUALITY was a 48-week, single-center, randomized, open-label clinical trial in ART-naive PWH, randomized (1:1) to receive ART with DTG + 3TC (2DR group) or DTG + FTC\/TAF (3DR group). We measured total and intact proviral HIV-1 DNA, cell-associated RNA in CD4+ T cells, frequency of HIV-infected CD4+ T cells able to produce p24, plasma soluble inflammatory markers, and activation and exhaustion markers in CD4+ and CD8+ T cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-four participants (22 per study arm) were enrolled, with baseline mean (standard deviation) log10 plasma viral load (pVL) 4.4 (0.7) copies\/mL and CD4+ T-cell counts of 493 (221) cells\/\u03bcL. At week 48, all participants had pVL &amp;lt;50\u2005copies\/mL at week 48, except for 1 participant in the 2DR group who was resuppressed after treating syphilis. Changes from baseline in reservoir parameters and immune biomarkers were comparable between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>First-line ART with DTG + 3TC showed similar reductions of HIV-1 persistence parameters and immune markers as DTG + FTC\/TAF, supporting DTG\/3TC among preferred first-line ART options for PWH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae530","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T11:36:41Z","timestamp":1730115401000},"page":"600-610","source":"Crossref","is-referenced-by-count":13,"title":["Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood"],"prefix":"10.1093","volume":"231","author":[{"given":"Luc\u00eda","family":"Bail\u00f3n","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol"},{"name":"Fundaci\u00f3 Lluita contra les Infeccions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Puertas","sequence":"additional","affiliation":[{"name":"Institute for Health Science Research Germans Trias i Pujol , Badalona"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid"},{"name":"IrsiCaixa , Badalona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Garc\u00eda-Guerrero","sequence":"additional","affiliation":[{"name":"IrsiCaixa , Badalona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1011-8849","authenticated-orcid":false,"given":"Igor","family":"Moraes-Cardoso","sequence":"additional","affiliation":[{"name":"Institute for Health Science Research Germans Trias i Pujol , Badalona"},{"name":"IrsiCaixa , Badalona"},{"name":"Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona , Cerdanyola del Vall\u00e9s"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Aparicio","sequence":"additional","affiliation":[{"name":"IrsiCaixa , Badalona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-8634","authenticated-orcid":false,"given":"Yovaninna","family":"Alarc\u00f3n-Soto","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Lluita contra les Infeccions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Rivero","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol"},{"name":"Fundaci\u00f3 Lluita contra les Infeccions"},{"name":"Projecte dels NOMS-Hispanosida, BCN CheckPoint , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-7281","authenticated-orcid":false,"given":"Elias P","family":"Rosen","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9652-6394","authenticated-orcid":false,"given":"Jacob D","family":"Estes","sequence":"additional","affiliation":[{"name":"Vaccine and Gene Therapy Institute"},{"name":"Oregon National Primate Research Center, Oregon Health & Science University , Beaverton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e0","family":"Blanco","sequence":"additional","affiliation":[{"name":"Institute for Health Science Research Germans Trias i Pujol , Badalona"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid"},{"name":"IrsiCaixa , Badalona"},{"name":"Department of Infectious Diseases and Immunity, University of Vic\u2013Central University of Catalonia , Vic, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9934-5759","authenticated-orcid":false,"given":"Alex","family":"Olvera","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid"},{"name":"IrsiCaixa , Badalona"},{"name":"Department of Infectious Diseases and Immunity, University of Vic\u2013Central University of Catalonia , Vic, Spain"},{"name":"Biosciences Department, Faculty of Sciences and Technology, University of Vic\u2013Central University of Catalonia , Vic ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-407X","authenticated-orcid":false,"given":"Beatriz","family":"Mothe","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol"},{"name":"Fundaci\u00f3 Lluita contra les Infeccions"},{"name":"Institute for Health Science Research Germans Trias i Pujol , Badalona"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid"},{"name":"IrsiCaixa , Badalona"},{"name":"Department of Infectious Diseases and Immunity, University of Vic\u2013Central University of Catalonia , Vic, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martinez-Picado","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid"},{"name":"IrsiCaixa , Badalona"},{"name":"Department of Infectious Diseases and Immunity, University of Vic\u2013Central University of Catalonia , Vic, Spain"},{"name":"Catalan Institution for Research and Advanced Studies , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4564-1963","authenticated-orcid":false,"given":"Jos\u00e9","family":"Molt\u00f3","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol"},{"name":"Fundaci\u00f3 Lluita contra les Infeccions"},{"name":"Institute for Health Science Research Germans Trias i Pujol , Badalona"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the DUALITY Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Blai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Francesc","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yovaninna","family":"Alarc\u00f3n-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Bail\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Benet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pep","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroa","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Sabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e0","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Garc\u00eda-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Marfil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martinez-Picado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Moraes-Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Olvera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwards","family":"Pradenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Puertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Urrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Desyaterik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias P","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Bondoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Busman-Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob D","family":"Estes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"2025031709154189900_jiae530-B1","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"2025031709154189900_jiae530-B2","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"2025031709154189900_jiae530-B3","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1038\/s41591-022-02060-2","article-title":"Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial","volume":"28","author":"Bail\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"2025031709154189900_jiae530-B4","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","article-title":"The Control of HIV After Antiretroviral Medication Pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies","volume":"218","author":"Namazi","year":"2018","journal-title":"J Infect Dis"},{"key":"2025031709154189900_jiae530-B5","doi-asserted-by":"crossref","first-page":"e0307821","DOI":"10.1128\/mBio.03078-21","article-title":"Atlas of the HIV-1 reservoir in peripheral CD4 T cells of individuals on successful antiretroviral therapy","volume":"12","author":"G\u00e1lvez","year":"2021","journal-title":"mBio"},{"key":"2025031709154189900_jiae530-B6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/QAD.0b013e328353f3f1","article-title":"HIV reservoirs: pathogenesis and obstacles to viral eradication and cure","volume":"26","author":"Chun","year":"2012","journal-title":"AIDS"},{"key":"2025031709154189900_jiae530-B7","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1128\/JVI.00674-16","article-title":"HIV DNA is frequently present within pathologic tissues evaluated at autopsy from combined antiretroviral therapy\u2013treated patients with undetectable viral loads","volume":"90","author":"Lamers","year":"2016","journal-title":"J Virol"},{"key":"2025031709154189900_jiae530-B8","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.0800050105","article-title":"Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy","volume":"105","author":"Palmer","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025031709154189900_jiae530-B9","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/QAD.0000000000003201","article-title":"Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression","volume":"36","author":"Fletcher","year":"2022","journal-title":"AIDS"},{"key":"2025031709154189900_jiae530-B10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000002287","article-title":"Antiretroviral therapy concentrations differ in gut vs. lymph node tissues and are associated with HIV viral transcription by a novel RT-ddPCR assay","volume":"83","author":"Lee","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025031709154189900_jiae530-B11","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/QAD.0b013e32835f2b49","article-title":"Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure","volume":"27","author":"Patterson","year":"2013","journal-title":"AIDS"},{"key":"2025031709154189900_jiae530-B12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3851\/IMP1919","article-title":"Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract","volume":"16","author":"Else","year":"2011","journal-title":"Antivir Ther"},{"key":"2025031709154189900_jiae530-B13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/psp4.12200","article-title":"A mathematical model to predict HIV virological failure and elucidate the role of lymph node drug penetration","volume":"6","author":"Sanche","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025031709154189900_jiae530-B14","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025031709154189900_jiae530-B15","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm.4411","article-title":"Defining total-body AIDS-virus burden with implications for curative strategies","volume":"23","author":"Estes","year":"2017","journal-title":"Nat Med"},{"key":"2025031709154189900_jiae530-B16","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.3389\/fimmu.2019.01965","article-title":"Systemic inflammation and the increased risk of inflamm-aging and age-associated diseases in people living with HIV on long term suppressive antiretroviral therapy","volume":"10","author":"Babu","year":"2019","journal-title":"Front Immunol"},{"key":"2025031709154189900_jiae530-B17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/path.2276","article-title":"Immune activation and inflammation in HIV-1 infection: causes and consequences","volume":"214","author":"Appay","year":"2008","journal-title":"J Pathol"},{"key":"2025031709154189900_jiae530-B18","doi-asserted-by":"crossref","first-page":"e2018099","DOI":"10.1001\/jamanetworkopen.2020.18099","article-title":"Association of viral persistence and atherosclerosis in adults with treated HIV infection","volume":"3","author":"McLaughlin","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025031709154189900_jiae530-B19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/COH.0000000000000227","article-title":"Immune activation and cardiovascular disease in chronic HIV infection","volume":"11","author":"Longenecker","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"2025031709154189900_jiae530-B20","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3389\/fimmu.2020.01321","article-title":"Associations between plasma immunomodulatory and inflammatory mediators with VACS Index scores among older HIV-infected adults on antiretroviral therapy","volume":"11","author":"Premeaux","year":"2020","journal-title":"Front Immunol"},{"key":"2025031709154189900_jiae530-B21","doi-asserted-by":"crossref","first-page":"e0148231","DOI":"10.1371\/journal.pone.0148231","article-title":"Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients","volume":"11","author":"Baril","year":"2016","journal-title":"PLoS One"},{"key":"2025031709154189900_jiae530-B22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hiv.12534","article-title":"Nucleoside reverse transcriptase inhibitor\u2013reducing strategies in HIV treatment: assessing the evidence","volume":"19","author":"Orkin","year":"2018","journal-title":"HIV Med"},{"key":"2025031709154189900_jiae530-B23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy\u2013naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"issue":":","key":"2025031709154189900_jiae530-B24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/QAI.0000000000003395","article-title":"Durable efficacy of switching from a 3- or 4-drug tenofovir alafenamide-based regimen to the 2-drug regimen dolutegravir\/lamivudine in the TANGO study through week 196","volume":"96","author":"De Wit","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025031709154189900_jiae530-B25","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review","volume":"10","author":"Patel","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2025031709154189900_jiae530-B26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025031709154189900_jiae530-B27","doi-asserted-by":"crossref","first-page":"106771","DOI":"10.1016\/j.ijantimicag.2023.106771","article-title":"Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor\u2013based regimen","volume":"61","author":"Scutari","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2025031709154189900_jiae530-B28","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/jac\/dkaa035","article-title":"Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial)","volume":"75","author":"Charpentier","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025031709154189900_jiae530-B29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/jac\/dkaa058","article-title":"Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir\/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study","volume":"75","author":"Lombardi","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025031709154189900_jiae530-B30","doi-asserted-by":"crossref","first-page":"1151.e9","DOI":"10.1016\/j.cmi.2022.02.041","article-title":"Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial","volume":"28","author":"Trujillo-Rodr\u00edguez","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025031709154189900_jiae530-B31","doi-asserted-by":"crossref","first-page":"e0175899","DOI":"10.1371\/journal.pone.0175899","article-title":"Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue","volume":"12","author":"Mor\u00f3n-L\u00f3pez","year":"2017","journal-title":"PLoS One"},{"key":"2025031709154189900_jiae530-B32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A novel quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"},{"key":"2025031709154189900_jiae530-B33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-020-20442-3","article-title":"HIV-1 diversity considerations in the application of the intact proviral DNA assay (IPDA)","volume":"12","author":"Kinloch","year":"2021","journal-title":"Nat Commun"},{"key":"2025031709154189900_jiae530-B34","doi-asserted-by":"crossref","first-page":"e0056021","DOI":"10.1128\/mBio.00560-21","article-title":"VIP-SPOT: an innovative assay to quantify the productive HIV-1 reservoir in the monitoring of cure strategies","volume":"12","author":"Puertas","year":"2021","journal-title":"mBio"},{"key":"2025031709154189900_jiae530-B35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0000000000000066","article-title":"Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection","volume":"28","author":"Puertas","year":"2014","journal-title":"AIDS"},{"key":"2025031709154189900_jiae530-B36","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1073\/pnas.1917876117","article-title":"Defective HIV-1 proviruses produce viral proteins","volume":"117","author":"Imamichi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025031709154189900_jiae530-B37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/v14050927","article-title":"Inflammatory markers after switching to a dual drug regimen in HIV-infected subjects: a two-year follow-up","volume":"14","author":"Vassallo","year":"2022","journal-title":"Viruses"},{"key":"2025031709154189900_jiae530-B38","doi-asserted-by":"crossref","first-page":"ofad626","DOI":"10.1093\/ofid\/ofad626","article-title":"Very-low-level viremia, inflammatory biomarkers, and associated baseline variables: three-year results of the randomized TANGO study","volume":"11","author":"Wang","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025031709154189900_jiae530-B39","doi-asserted-by":"crossref","first-page":"ofac068","DOI":"10.1093\/ofid\/ofac068","article-title":"Changes in inflammatory and atherogenesis biomarkers with the 2-drug regimen dolutegravir plus lamivudine in antiretroviral therapy\u2013experienced, virologically suppressed people with HIV-1. A systematic literature review","volume":"9","author":"Llibre","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025031709154189900_jiae530-B40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAI.0000000000003019","article-title":"Brief report: evaluation of inflammation and atherogenesis biomarkers through 148 weeks postswitch to dolutegravir and rilpivirine in SWORD-1\/SWORD-2","volume":"91","author":"Llibre","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025031709154189900_jiae530-B41","doi-asserted-by":"crossref","first-page":"904689","DOI":"10.3389\/fimmu.2022.904689","article-title":"Long-term changes of inflammatory biomarkers in individuals on suppressive three-drug or two-drug antiretroviral regimens","volume":"13","author":"Serrano-Villar","year":"2022","journal-title":"Front Immunol"},{"key":"2025031709154189900_jiae530-B42","first-page":"179","article-title":"Impact of switching from dual to triple therapy on inflammation: iNSTINCT study. [CROI abstract 644]. In special issue: abstract from the CROI 2024 Conference on Retroviruses and Opportunistic Infections","volume":"3","author":"Serrano-Villar","year":"2024","journal-title":"Top Antivir Med"},{"key":"2025031709154189900_jiae530-B43","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/cpt.2186","article-title":"The lymph node reservoir: physiology, HIV infection, and antiretroviral therapy","volume":"109","author":"Scholz","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2025031709154189900_jiae530-B44","doi-asserted-by":"crossref","first-page":"e00019-21","DOI":"10.1128\/AAC.00019-21","article-title":"Quantitative imaging analysis of the spatial relationship between antiretrovirals, reverse transcriptase simian-human immunodeficiency virus RNA, and collagen in the mesenteric lymph nodes of nonhuman primates","volume":"65","author":"Scholz","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031709154189900_jiae530-B45","doi-asserted-by":"crossref","first-page":"e25895","DOI":"10.1002\/jia2.25895","article-title":"Antiretroviral drug exposure in lymph nodes is heterogeneous and drug dependent","volume":"25","author":"Rosen","year":"2022","journal-title":"J Int AIDS Soc"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae530\/60717292\/jiae530.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/3\/600\/60717292\/jiae530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/3\/600\/60717292\/jiae530.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:16:09Z","timestamp":1742202969000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/3\/600\/7846276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,28]]},"published-print":{"date-parts":[[2025,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae530","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3,15]]},"published":{"date-parts":[[2024,10,28]]}}}